These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 22947591

  • 1. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J, Kim MG, Choi B, Han NY, Yun HY, Yoon JH, Oh JM.
    Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P.
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S, Saint-Marcoux F, Rousseau A, Zhang D, Leroy V, Marquet P, Jacqz-Aigrain E.
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [Abstract] [Full Text] [Related]

  • 5. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, Raisjalal GH, Rahsaz M, Pourgholami A, Sagheb F.
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [Abstract] [Full Text] [Related]

  • 6. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis.
    Kim IW, Yun HY, Choi B, Han N, Park SY, Lee ES, Oh JM.
    Clin Ther; 2012 Aug; 34(8):1816-26. PubMed ID: 22796246
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N, Rousseau A, Hoizey G, Rerolle JP, Toupance O, Le Meur Y, Marquet P.
    Clin Pharmacokinet; 2006 Aug; 45(11):1135-48. PubMed ID: 17048977
    [Abstract] [Full Text] [Related]

  • 8. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.
    Zhu HJ, Yuan SH, Fang Y, Sun XZ, Kong H, Ge WH.
    Pharmacogenomics J; 2011 Jun; 11(3):237-46. PubMed ID: 20368718
    [Abstract] [Full Text] [Related]

  • 9. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT, Mourad M, Haufroid V, Delattre IK, Verbeeck RK, Wallemacq P.
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [Abstract] [Full Text] [Related]

  • 10. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ.
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [Abstract] [Full Text] [Related]

  • 11. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
    Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, Lee JI, Oh JM, Kim IW.
    Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
    [Abstract] [Full Text] [Related]

  • 13. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
    Tirelli S, Ferraresso M, Ghio L, Meregalli E, Martina V, Belingheri M, Mattiello C, Torresani E, Edefonti A.
    Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of cyclosporine in clinical renal transplant patients.
    Wu KH, Cui YM, Guo JF, Zhou Y, Zhai SD, Cui FD, Lu W.
    Drug Metab Dispos; 2005 Sep; 33(9):1268-75. PubMed ID: 15932953
    [Abstract] [Full Text] [Related]

  • 15. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [Abstract] [Full Text] [Related]

  • 16. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ.
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [Abstract] [Full Text] [Related]

  • 17. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Macphee IA, de Fijter JW, van Gelder T.
    Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
    [Abstract] [Full Text] [Related]

  • 18. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provôt F, Hazzan M, Noël C, Broly F, Cauffiez C.
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [Abstract] [Full Text] [Related]

  • 19. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
    Żochowska D, Wyzgał J, Pączek L.
    Ann Transplant; 2012 Sep; 17(3):36-44. PubMed ID: 23018254
    [Abstract] [Full Text] [Related]

  • 20. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH.
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.